Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $242 from $217 and keeps an Equal Weight rating on the shares. The firm notes that its updated sales estimates for Auvelity in MDD and ADA are $2.2B and $2.1B, respectively, which remain “conservative” compared to management’s $8B guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $302 from $242 at RBC Capital
- Axsome Therapeutics price target raised to $310 from $228 at Mizuho
- Axsome Therapeutics price target raised to $246 from $241 at Baird
- Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright
- Axsome Therapeutics price target raised to $276 from $239 at BofA